ACE2 and COVID-19: In all carriers of genotypes ACE1 rs1799752 and ACE2 rs1978124, the amount of IL-6 was noticeably increased in the control group compared with the COVID-19 group, as well as outpatients compared with inpatients, and in the survived compared with the expired (Supplementary Tables S9-S11).